FSD Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Toronto, on / accesswire / april 22, 2024 / fsd pharma inc. (nasdaq:huge)(cse:huge)(fra:0k9a) ("fsd pharma"), provides an update by way of a news release issued by celly nutrition corp. ("celly nu"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness. on april 22, 2024, celly nu announced a strategic partnership with bevsource, a leading provider of beverage development, production and operations solutions in st. paul, minnesota as follows: toronto, ontario, april 22, 2024 - in a strategic move in preparation of the launch in the united states of its scientifically formulated dietary supplement, unbuzzd™, celly nutrition corp...

Toronto, on / accesswire / april 17, 2024 / fsd pharma inc. (nasdaq:huge)(cse:huge)(fra:0k9a) ("fsd pharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced the expansion of its pipeline into metabolic and related disorders including weight loss and liver health. the company has initiated investigations into ingredients and dietary supplements that may have the potential to promote weight loss and liver health.

Toronto, on / accesswire / april 15, 2024 / fsd pharma inc. (nasdaq:huge)(cse:huge)(fra:0k9a) ("fsd pharma"), provides an update on its investment in celly nutrition corp. ("celly nu"), a privately held canadian company launching an innovative beverage product that can assist in expediting alcohol metabolism and faster recovery from alcohol consumption. on april 8, 2024, celly nu announced an investment by fsd complete press release is referenced below; toronto, ontario--(newsfile corp. - april 8, 2024) - celly nutrition corp. ("celly nu" or the "company"), announced today that it has entered into a loan amending agreement (the "agreement") in connection with the senior secured term loan made by fsd pharma inc...

Toronto, ontario--(newsfile corp. - april 7, 2024) - fsd pharma inc. (nasdaq: huge) (cse: huge) (fse: 0k9) ("fsd pharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on april 5, 2024 it received a written notification (the "notification letter") from the nasdaq stock market llc ("nasdaq") that the company is not in compliance with the minimum bid price requirement set forth in nasdaq's rules for continued listing on the nasdaq capital market. the notification letter is only a notification of deficiency and not a notice of delisting.

Toronto, on / accesswire / april 1, 2024 / fsd pharma inc. (nasdaq:huge)(cse:huge)(fra:0k9a) ("fsd pharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that the company filed its audited annual financial results for the fourth quarter and full year ended december 31, 2023 and accompanying management's discussion and analysis on thursday march 28, 2024 and today filed its annual report on 20-f for the year ended december 31, 2023. these filings are available for review on the company's sedar+ profile at www.sedarplus.ca and the company's edgar profile at www...

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) told investors it has received a No Objection Letter (NOL) from Health Canada for its proposed Phase 1 clinical trial of LUCID-21-302 (Lucid-MS), a novel drug candidate for the treatment of multiple sclerosis (MS), providing it with regulatory approval to move forward with the trial in Canada. The Toronto-based biopharmaceutical company said the first-in-human clinical trial will evaluate the safety and tolerability of Lucid-MS, a neuroprotective compound with a unique mechanism of action for the treatment of MS.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) at two clinical sites in the US while a Canadian site is to be ready to recruit soon. The Toronto-based biopharmaceutical company said FSD201 is a proprietary anti-inflammatory compound with the potential to address a wide range of inflammatory diseases and associated conditions.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (MS). In a statement, FSD Pharma called Lucid-MS a “first-in-class neuroprotective compound” with a novel mechanism action that has shown to prevent myelin degradation, which can cause MS and other neurodegenerative diseases.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months.  “FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company's interim CEO Anthony Durkacz said in a statement.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors it has also appointed a number of new doctors to its Scientific and Clinical Expert Committee and is investigating other products addressing acute medical needs due to substances of abuse such as alcohol.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201.   The Toronto-based biopharma firm said the corresponding study protocol is titled "A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma (CSE:HUGE, NASDAQ:HUGE).